Kailera Therapeutics, Inc. Common Stock (NASDAQ:KLRA) — Market Cap & Net Worth
Market Cap & Net Worth: Kailera Therapeutics, Inc. Common Stock (KLRA)
Kailera Therapeutics, Inc. Common Stock (NASDAQ:KLRA) has a market capitalization of $1.30 Billion ($1.30 Billion) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7755 globally and #2306 in its home market, demonstrating a -12.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kailera Therapeutics, Inc. Common Stock's stock price $10.00 by its total outstanding shares 129643676 (129.64 Million).
Kailera Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Kailera Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.30 Billion to $1.30 Billion (0.00% CAGR). Check Kailera Therapeutics, Inc. Common Stock (KLRA) share price today for real-time trading data and today's change.
Kailera Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kailera Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Kailera Therapeutics, Inc. Common Stock (KLRA) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KLRA by Market Capitalization
Companies near Kailera Therapeutics, Inc. Common Stock in the global market cap rankings as of October 10, 2026. See debt-free asset ratio of Kailera Therapeutics, Inc. Common Stock to understand what proportion of total assets are financed by equity.
Key companies related to Kailera Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.55 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $74.80 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $62.29 Billion USD ( AU$88.04 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.55 Billion | $503.25 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $739.57 |
| #450 | CSL Ltd | AU:CSL | $62.29 Billion | AU$181.46 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $197.00 |
Kailera Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Kailera Therapeutics, Inc. Common Stock's market cap moved from $1.30 Billion to $ 1.30 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 9th, 2026 the market cap of Kailera Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.30 Billion USD |
| MoneyControl | $1.30 Billion USD |
| MarketWatch | $1.30 Billion USD |
| marketcap.company | $1.30 Billion USD |
| Reuters | $1.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral … Read more